Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Melanoma 2Breast Neoplasms 2Wilms Tumor 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Ewing 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Lymphoma, Non-Hodgkin 1Leukemia, Lymphocytic, Chronic, B-Cell 1Kidney Neoplasms 1Hepatoblastoma 1Endometrial Neoplasms 1Desmoid Tumors 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Carcinoma In Situ 1

Interventions

Temozolomide 7Vincristine 5Cyclophosphamide 5X-Rays 4Specimen Handling 4Phantoms, Imaging 4Magnetic Resonance Spectroscopy 4Irinotecan 4cabozantinib 3Ifosfamide 3Etoposide 3Doxorubicin 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2palbociclib 2liposomal doxorubicin 2ivosidenib 2fludarabine 2Topotecan 2Radiation 2Nuclear Medicine Department, Hospital 2LY3023414 2Eflornithine 2Congresses as Topic 2trifluridine tipiracil drug combination 1talazoparib 1silmitasertib 1romiplostim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Ewing × Absorptiometry, Photon × 90 days × Clear all
NCT04851119 2026-05-05

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Children's Oncology Group

Phase 1/2 Recruiting
147 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidSarcoma

Carcinoma, Hepatocellular, Lymphoma, Non-Hodgkin, Melanoma, Wilms Tumor, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Ewing, Osteosarcoma, Colorectal Neoplasms, Endometrial Neoplasms, Hepatoblastoma, Desmoid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡